Corbus Pharmaceuticals Holdings (CRBP) Cash & Equivalents (2013 - 2025)

Corbus Pharmaceuticals Holdings' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $28.5 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 65.67% year-over-year to $28.5 million; the TTM figure through Dec 2025 stood at $28.5 million (up 65.67% YoY), while the FY2025 annual figure was $28.5 million, up 65.67% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $28.5 million, up from $27.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $66.6 million in Q1 2021, with the low at $7.3 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $19.7 million (2024), against an average of $24.3 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 87.16% in 2023, then jumped 183.69% in 2024.
• Corbus Pharmaceuticals Holdings' Cash & Equivalents stood at $25.0 million in 2021, then plunged by 32.01% to $17.0 million in 2022, then declined by 19.28% to $13.7 million in 2023, then rose by 25.31% to $17.2 million in 2024, then jumped by 65.67% to $28.5 million in 2025.
• Business Quant data shows CRBP's Cash & Equivalents at $28.5 million in Q4 2025, $27.0 million in Q3 2025, and $20.0 million in Q2 2025.